Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series

Abstract

Psychiatric adverse drug reactions (ADRs) have been reported with statin use, but the literature regarding statin-associated mood/behavioral changes remains limited. We sought to elicit information germane to natural history and characteristics of central nervous system/behavioral changes in apparent connection with statin and/or cholesterol-lowering drug use, and delineate mechanisms that may bear on an association. Participants (and/or proxies) self-referred with behavioral and/or mood changes in apparent association with statins completed a survey eliciting cholesterol-lowering drug history, character and impact of behavioral/mood effect, time-course of onset and recovery in relation to drug use/modification, co-occurrence of recognized statin-associated ADRs, and factors relevant to ADR causality determination. Naranjo presumptive ADR causality criteria were assessed. Participants (n = 12) reported mood/behavior change that commenced following statin initiation and persisted or progressed with continued use. Reported problems included violent ideation, irritability, depression, and suicide. Problems resolved with drug discontinuation and recurred with rechallenge where attempted. Eight met presumptive criteria for “probable” or “definite” causality; others had additional factors not considered in Naranjo criteria that bear on casual likelihood. (1) Simvastatin 80 mg was followed in 5 days by irritability/depression culminating in suicide in a man in his 40s (Naranjo criteria: possible causality). (2) Simvastatin 10 mg was followed within 2 weeks by depression in a woman in her 50s (probable causality). (3) Atorvastatin 20 mg was followed in ~1 month by depression and irritability/aggression in a male in his 50s (probable causality). (4) Atorvastatin 10 mg was followed in several months by aggression/irritability and depression culminating in suicide in a man in his 40s (possible causality). (5) Fenofibrate + rosuvastatin (unknown dose), later combined with atorvastatin were followed in 1 month by aggression/irritability in a male in his 30s (probable causality). (6) Lovastatin (unknown dose and time-course to reaction) was followed by depression, dyscontrol of bipolar disorder, and suicide attempts in a male in his 40s (possible causality). (7) Atorvastatin 20 mg was followed within 2 weeks by cognitive compromise, and nightmares, depression, and anxiety culminating in suicide in a man in his teens (definite causality). (8) Simvastatin 10 mg was followed (time-course not recalled) by depression, aggression/irritability culminating in suicide in a man in his 60s (possible causality). (9) Simvastatin 20 mg then atorvastatin 10 mg were followed (time-course not provided) by irritability/aggression in a man in his 60s (definite causality). (10) Atorvastatin 10 then 20 then 40 mg were followed shortly after the dose increase by violent ideation and anxiety in a man in his 30s (probable causality). (11) Atorvastatin 20 mg and then simvastatin 20 mg were followed in 2 weeks by aggression/irritability in a man in his...

PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder

“…Clinically, the use of PCSK9 inhibitors has raised questions about neurocognitive side effects (Koren et al., ; Walker, ), although this is controversial as recent data do not support major effects on cognitive function (Giugliano et al., ). Furthermore, a recent study suggested a possible link between PCSK9 inhibitors and depression (Alghamdi et al., ), which is in line with long‐standing concerns about lipid‐lowering drugs and their association with depression (Cham et al., ; Hyyppa et al., ; Lohoff, ; Morales et al., ).…”

The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms

“…Post-marketing surveillance has continued to uncover case reports of cognitive effects associated with statin use since the FDA report. A case series aimed to describe the potential behavioral and psychiatric changes in statin users and found most of the adverse reports met presumptive criteria for “probable” or “definite” causality by the Naranjo score [ 20 ]. Consistent with previous reports, lipophilic statins (atorvastatin, simvastatin, and lovastatin) were identified as the most commonly associated with cognitive impairment ( Table 1 ).…”

Proanthocyanidins Ameliorated Deficits of Lipid Metabolism in Type 2 Diabetes Mellitus Via Inhibiting Adipogenesis and Improving Mitochondrial Function

“…At present, the most prescribed medications for hyperlipidemia in diabetes include Fibrates and Stains. However, side effects of Fibrates and Stains [7][8][9] makes it significant to develop functional foods-and natural products-based treatments which could be safer and more tolerable for patients.…”